Chronic Lymphocytic Leukemia, Lymphocytic Lymphoma or Waldenstrom Disease
Conditions
Brief summary
The COVID-19 epidemic (Coronavirus Disease 2019) which is currently raging in France is an emerging infectious disease linked to a virus of the genus coronavirus (SARS-CoV-2). The first cases were reported in Wuhan, China, in late December 2019 \[1\]. Globally, it has been placed in the pandemic stage by the WHO since March 11, 2020. Coronavirus viruses have been responsible for epidemics in the past such as the SARS epidemic in 2002 (Syndrome Severe Acute Respiratory) linked to the SARS-CoV virus, or the epidemic of MERS (Middle East Respiratory Syndrome) that affected the Middle East in 2012. Patients with chronic lymphocytic leukemia (CLL) / lymphocytic lymphoma or Waldenstrom Disease (WD) therefore represent a population at high risk of developing a severe form in the event of COVID-19 infection. To date, no data is available in the literature to assess the impact of the COVID-19 epidemic in this population of patients with CLL / lymphocytic lymphoma or WD.
Interventions
BEHAVIORALData registry
Collection of clinical data, treatment regimens and survival data
Sponsors
Institut de cancérologie Strasbourg Europe
French Innovative Leukemia Organisation
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Diagnosis of chronic lymphocytic leukemia / lymphocytic lymphoma or Waldenstrom disease according to the criteria of the WHO 2016 with a proven or probable infection by COVID-19 according to the following criteria: * Proven infection: PCR positive regardless of the radio-clinical picture (Other tests made available later and having good diagnostic performance will be accepted) * Probable infection: the diagnosis of probable infection is retained in case of negative PCR or not made if presence of at least 2 major criteria or of a major criterion associated with at least 2 minor criteria among the following, in the absence other documented cause. * Major criteria: * Fever * Loss of smell / taste * At least one respiratory sign among cough, dyspnea, chest pain * Radiological signs suggestive of the scanner (areas or diffuse appearance of frosted glass, condensations including pseudonodular condensations, association of frosted glass and condensation within the same lesion, nodules and micronodules, thickening of the interlobular septa) or on an X-ray of the thorax ( interstitial, alveolo-interstitial or alveolar syndrome, unilateral or bilateral) * Notion of storytelling with a person whose SARS-CoV-2 infection has been formally documented * Minor criteria * Aches * Sore throat * Rhinorrhea * Headache * Diarrhea * Abdominal pain * Frank asthenia * Conjunctivitis
Exclusion criteria
* Patient opposition
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Prognostic factors for healing of COVID-19 infection | Day 0 | Hematological pathology Description |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Medical care of Coronavirus infection | within 12 months after diagnosis | Describe the management carried out concerning Coronavirus infection and its impact on the treatment of hemopathy. |
| national epidemiological monitoring | through study completion, an average of 2 years | Allow national epidemiological monitoring and regularly inform the hematology community. |
Countries
France
Outcome results
None listed